Former Gilead CEO lands on board of East Bay gene therapy company seeking $75M IPO

4D Molecular Therapeutics' gene therapies are mainly focused on the eyes, but includes potential one-and-done treatments for Fabry disease and cystic fibrosis.

Click to view original post